Gilead Generates Street Skepticism Ahead of Covid-19 Results .
2020-04-07 13:58:02 +00:00 .
( Bloomberg ) --
Results from a study of Gilead Sciences Inc. ’s experimental Covid-19 medicine are top - of - mind for Wall Street as cases surpass(#before 2020-04-07 13:58:02) 1.35 million and deaths(#before 2020-04-07 13:58:02) approach(#overlap 2020-04-07 13:58:02) 76,000 .
With a potential vaccine more than a year away , Gilead Sciences Inc. ’s antiviral remdesivir offers(#overlap 2020-04-07 13:58:02) one of the nearest - term hopes for a treatment(#after 2020-04-07 13:58:02) in the pandemic(#before 2020-04-07 13:58:02) that ’s sweeping(#overlap 2020-04-07 13:58:02) across the globe and putting(#before 2020-04-07 13:58:02) many countries , including(#before 2020-04-07 13:58:02) most of the U.S. , on lockdown(#overlap 2020-04-07 13:58:02) .
Results from late - stage studies out of China are expected(#included May.) this month with results from U.S. trials following(#included this month) in May.
After the company ’s valuation surged(#included late January) more than $ 20 billion from late January to early March , some Wall Street analysts are cautioning(#overlap 2020-04-07 13:58:02) there may not be much more room for shares to gain(#after 2020-04-07 13:58:02) .
The stock has traded(#before 2020-04-07 13:58:02) sideways since hitting(#included March 6) a two - year high on March 6 .
“ We see(#before 2020-04-07 13:58:02) a highly negatively skewed risk / reward , ” Barclays analysts led by Carter Gould warned(#included 2020-04) ahead of the April data .
Barclays analysts led by Carter Gould rate(#overlap 2020-04-07 13:58:02) Gilead underweight .
Barclays is assigning(#overlap 2020-04-07 13:58:02) a 20 % chance that the two studies out of China --- one in patients with mild to moderate symptoms and another in the severely ill -- will succeed(#after 2020-04-07 13:58:02) .
Even if the pair hit(#before 2020-04-07 13:58:02) the mark , Gilead Sciences Inc. ’s gains(#before 2020-04-07 13:58:02) could lead(#before 2020-04-07 13:58:02) to a sell - off on “ the commercial realities facing(#overlap 2020-04-07 13:58:02) remdesivir , ” Barclays analysts led by Carter Gould said(#before 2020-04-07 13:58:02) .
That could include(#before 2020-04-07 13:58:02) a complex manufacturing(#before 2020-04-07 13:58:02) process and the difficulties pricing and selling(#before 2020-04-07 13:58:02) a drug for a global pandemic(#before 2020-04-07 13:58:02) .
Covid-19 patients in the two studies out of China --- one in patients with mild to moderate symptoms and another in the severely ill -- are likely getting(#before 2020-04-07 13:58:02) treated(#after 2020-04-07 13:58:02) after the virus has already reached the height of the virus powers in the body , instead of before when a treatment could potentially be more effective , Barclays said(#before 2020-04-07 13:58:02) .
If the two studies out of China --- one in patients with mild to moderate symptoms and another in the severely ill -- fail(#before 2020-04-07 13:58:02) , Gilead shares could fall(#after 2020-04-07 13:58:02) back to the low-$60 range where Gilead shares traded(#before 2020-04-07 13:58:02) before the crisis(#before 2020-04-07 13:58:02) .
Wall Street investors have been scrambling(#before 2020-04-07 13:58:02) to position(#before 2020-04-07 13:58:02) Wall Street investors ahead of the data .
Gilead appeared(#included 2020) not only as a top long pick for investors in 2020 but also among the top short picks(#included 2020) in a JPMorgan Chase Co. buy(#included 2020) - side survey(#before 2020-04-07 13:58:02) .
Options data suggest(#overlap 2020-04-07 13:58:02) The stock could swing(#included May 1) 17 % in either direction by May 1 .
Bearish bets against Gilead peaked(#included March 19) at $ 1.97 billion on March 19 , according to data from financial analytics firm S3 Partners .
The stock was ripe(#included two weeks ago) for a short squeeze(#included two weeks ago) two weeks ago but peaked ’s no longer the case , S3 ’s Ihor Dusaniwsky said(#included Monday) Monday .
Gilead is still one of the top three largest short stories in the biotech sector with $ 1.77 billion , or 1.8 % of Gilead float , shorted(#included Monday) as of Monday , S3 ’s Ihor Dusaniwsky said(#included Monday) .
Even the bulls have(#overlap 2020-04-07 13:58:02) doubts about the data .
Evercore ISI analyst Umer Raffat , who has an outperform rating on the stock , said(#before 2020-04-07 13:58:02) Evercore ISI analyst Umer Raffat , who has an outperform rating on the stock , expects(#overlap 2020-04-07 13:58:02) the study in severely ill patients “ may underwhelm(#before 2020-04-07 13:58:02) , ” though Evercore ISI analyst Umer Raffat , who has an outperform rating on the stock , said(#before 2020-04-07 13:58:02) remdesivir could help(#before 2020-04-07 13:58:02) those who received the drug early enough in those who received the drug course of treatment(#before 2020-04-07 13:58:02) .
Optimism that Gilead has started(#before 2020-04-07 13:58:02) ramping(#before 2020-04-07 13:58:02) up production(#before 2020-04-07 13:58:02) because Gilead knows(#before 2020-04-07 13:58:02) the medicine works is also unfounded , Evercore ISI analyst Umer Raffat , who has an outperform rating on the stock , said(#before 2020-04-07 13:58:02) , noting(#included Monday) management confirmed(#before 2020-04-07 13:58:02) management have n’t seen(#before 2020-04-07 13:58:02) results from U.S. trials .
For antivirals , “ it is NOT about the overall trial(#before 2020-04-07 13:58:02) result , ” Evercore ISI analyst Umer Raffat , who has an outperform rating on the stock , said(#before 2020-04-07 13:58:02) .
“ All that matters(#before 2020-04-07 13:58:02) is being able to identify(#before 2020-04-07 13:58:02) the time point post - infection until which you can initiate(#before 2020-04-07 13:58:02) an antiviral and expect(#before 2020-04-07 13:58:02) efficacy . ”
For more articles like this , please visit us at bloomberg.com Subscribe now to stay(#included PRESENT_REF) ahead with the most trusted(#included PRESENT_REF) business news source .
© 2020 Bloomberg L.P.
